DRUG
Liraglutide injection
Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
Status
Recruiting
Phase
Phase 3
Enrollment
260
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.
Full detailed description
Delirium is the most prevalent neurological complication following cardiac surgery. It is characterized by an acute and fluctuating disturbance in consciousness, attention, and cognitive function. The incidence of delirium post-cardiac surgery ranges between 11% and 46%. It is closely linked to increased postoperative mortality, extended hospital stays, higher healthcare costs, and long-term cognitive impairment. Currently, it is widely recognized that the development of delirium is influenced by multiple factors, including advanced age, diabetes, surgical and anesthetic techniques, depression, baseline cognitive function, and infections, among others. Inflammatory responses, crucial for protecting against external or internal threats, can, following surgery, lead to neuroinflammation and neurological damage due to elevated postoperative inflammatory markers and blood-brain barrier disruption. The involvement of microglia and astrocytes, key players in the central nervous system's immune response, has been identified in mediating postoperative delirium, making them potential targets for prevention. Liraglutide, a Glucagon-like peptide-1 receptor agonist primarily used for treating Type 2 diabetes, has shown promise in mitigating neurocognitive damage associated with diabetes and Alzheimer's disease, suggesting its potential in preventing postoperative delirium in cardiac surgery patients with Type 2 diabetes. Preliminary animal studies and a randomized controlled trial indicate that perioperative liraglutide application could reduce the incidence of postoperative delirium by inhibiting glial activation and the subsequent neuroinflammatory response. However, differences in patient demographics, disease severity, and dosing in previous studies highlight the need for further investigation. The study aims to investigate whether the perioperative administration of liraglutide can prevent the onset of postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery. Secondary objectives include assessing the impact on the severity and duration of delirium, cognitive function, anxiety, depression, cardiac function, cardiovascular events, ICU stay, mechanical ventilation duration, and levels of serum markers for brain injury, inflammation, myocardial damage, and cardiac function.
Interventions
Treatment arms and agents.
DRUG
Placebo injection
Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
Timeline
From registration to results.
First posted
Apr 11, 2024
Study start
Nov 19, 2024
Primary completion
Mar 31, 2027
Study completion
Mar 31, 2028
Results posted
Not reported
Registry updated
Dec 20, 2024
Outcomes
What the study measures.
Primary outcomes
The incidence of delirium
Time frame · One day before surgery and within the first seven days after surgery.
Confusion Assessment Method (CAM), or its variant for the Intensive Care Unit, known as CAM-ICU, is the tool used to assess the incidence of delirium. For CAM, the scale ranges from a minimum value of 11 to a maximum of 44, with higher scores indicating a worse outcome. In contrast, CAM-ICU does not utilize a numerical scale; it is a qualitative assessment designed to evaluate confusion without assigning specific values.
Secondary outcomes
The severity of delirium
Time frame · One day before surgery and within the first seven days after surgery.
The CAM-Severity Scale (CAM-S), available in both short-form and long-form versions, serves as a tool for assessing the severity of delirium. The scale extends from 0 to 7 in its short-form and from 0 to 19 in its long-form. Higher scores on the CAM-S are indicative of more severe outcomes.
Cognitive function
Time frame · One day before surgery; one week after surgery or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Minimum Mental State Examination (MMSE) is the tool used to assess cognitive function. The scale extends from 0 to 30, with higher scores indicating a better outcome.
Anxiety
Time frame · One day before surgery; one week after surgery or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Generalized anxiety disorder-7 (GAD-7) is the tool used to assess anxiety. The scale extends from 0 to 21, with higher scores indicating a worse outcome.
Depression
Time frame · One day before surgery; one week after surgery or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Patient Health Questionnaire-9 (PHQ-9) is the tool used to assess depression. The scale extends from 0 to 27, with higher scores indicating a worse outcome.
Duration of ICU stay
Time frame · The time from transfer into the ICU to discharge from the ICU, assessed up to 12months.
By retrieving the Hospital Information System and ICU special care sheet
Mechanical ventilation time
Time frame · The time from tracheal intubation to the removal of the tracheal tube, assessed up to 12months.
By retrieving the Hospital Information System and ICU special care sheet
Duration of hospital stay
Time frame · The time from hospital admission to discharge, assessed up to 12months.
By retrieving the Hospital Information System
In-hospital mortality
Time frame · The time from hospital admission to discharge, assessed up to 12months.
By retrieving the Hospital Information System
Incidence of adverse events
Time frame · One day preoperatively to three days Postoperatively.
By retrieving the Hospital Information System, ICU special care sheet and follow-up
Rate of major cardiovascular adverse events
Time frame · Within 1 year post-surgery (including cardiovascular death, myocardial infarction, and stroke)
By retrieving the Hospital Information System, ICU special care sheet and follow-up
Eligibility
Who can take part.
- Minimum age
- 60 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: 1. Age ≥ 60 years 2. Type 2 diabetes 3. Patients undergoing elective cardiac surgery Exclusion Criteria: 1. History of neurological or psychiatric disorders, such as schizophrenia, epilepsy, Parkinson's disease, severe dementia, etc 2. Patients with communication difficulties, such as severe visual, auditory, or speech impairments 3. History of central nervous system damage or surgery 4. Cardiac function NYHA Class IV 5. Severe liver dysfunction (Child-Pugh Class C) 6. Severe renal failure requiring renal replacement therapy 7. History of pancreatitis 8. Type 1 diabetes 9. Patients whose blood sugar is difficult to control within 4-8 mmol/L during the screening period 10. Patients with medullary thyroid carcinoma or a family history of it 11. Pregnant or breastfeeding women 12. Intolerance or allergy to liraglutide 13. Previous use of GLP-1A and SGLT2i 14. Patients who refuse to sign the informed consent
Study locations
1 registered sites.
China. Showing up to 24 locations stored in the fast local snapshot.
Wenxue liu
Nanjing, Jiangsu, China
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Liraglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
4Moving Biotech · Knee Osteoarthritis · Synovitis of Knee
Phase 2
Active, not recruiting
129
2026-07
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Type 2 Diabetes Mellitus · Mild Cognitive Impairment
Not applicable
Completed
396
2026-07
Phase 1
Recruiting
71
2026-07
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
78
2026-07
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
West China Hospital · Alzheimer Disease · Diabetes Mellitus Type 2
Not applicable
Completed
213,891
2026-07
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
Indiana University · Obesity
Not applicable
Enrolling by invitation
125,000
2026-06
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.